ID: ALA2347578

Max Phase: Preclinical

Molecular Formula: C19H25FN6O2

Molecular Weight: 388.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC[C@H](CO)Nc1nc(NCc2cc(F)ccc2O)c2ncn(C(C)C)c2n1

Standard InChI:  InChI=1S/C19H25FN6O2/c1-4-14(9-27)23-19-24-17(16-18(25-19)26(10-22-16)11(2)3)21-8-12-7-13(20)5-6-15(12)28/h5-7,10-11,14,27-28H,4,8-9H2,1-3H3,(H2,21,23,24,25)/t14-/m1/s1

Standard InChI Key:  MKNHQUCYYAXXMU-CQSZACIVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 388.45

Molecular Weight (Monoisotopic): 388.2023

AlogP: 3.05

#Rotatable Bonds: 8

Polar Surface Area: 108.12

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.93

CX Basic pKa: 5.20

CX LogP: 2.73

CX LogD: 2.72

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.47

Np Likeness Score: -0.85

References

1. Zatloukal M, Jorda R, Gucký T, Řezníčková E, Voller J, Pospíšil T, Malínková V, Adamcová H, Kryštof V, Strnad M..  (2013)  Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.,  61  [PMID:22770608] [10.1016/j.ejmech.2012.06.036]

Source

Source(1):

• Scientific Literature